Daratumumab as maintenance therapy for transplant-eligible patients with NDMM: What have we learned from GRIFFIN and CASSIOPEIA trials? episode artwork

EPISODE · Jan 14, 2022 · 13 MIN

Daratumumab as maintenance therapy for transplant-eligible patients with NDMM: What have we learned from GRIFFIN and CASSIOPEIA trials?

from Multiple Myeloma Hub

During the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Jacob Laubach, Dana-Farber Cancer Institute, Boston, US, and Peter Voorhees, Levine Cancer Institute, Charlotte, US. We asked, Daratumumab as maintenance therapy for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM): What have we learned from GRIFFIN and CASSIOPEIA trials?In this podcast, Laubach and Voorhees discuss the findings from the randomized phase II GRIFFIN trial (NCT02874742) and the CASSIOPEIA trial (NCT02541383).  Hosted on Acast. See acast.com/privacy for more information.

Episode metadata supplied by the publisher feed · Published Jan 14, 2022

Embed this episode

NOW PLAYING

Daratumumab as maintenance therapy for transplant-eligible patients with NDMM: What have we learned from GRIFFIN and CASSIOPEIA trials?

0:00 13:24

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of Multiple Myeloma Hub?

This episode is 13 minutes long.

When was this Multiple Myeloma Hub episode published?

This episode was published on January 14, 2022.

Can I download this Multiple Myeloma Hub episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!